Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2002-11-12
2010-10-12
Anderson, James D (Department: 1614)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
Reexamination Certificate
active
07812044
ABSTRACT:
Remedies/preventives for hormone-independent cancer, hormone-independent cancer cell proliferation inhibitors, apoptosis inducers for cancer cells, etc. each containing a compound having an angiotensin II antagonism, its prodrug or a salt thereof. Thus, excellent anticancer agents are provided.
REFERENCES:
patent: 6004989 (1999-12-01), Naka et al.
patent: 6641811 (2003-11-01), Suthanthiran et al.
patent: 6833381 (2004-12-01), Ikeya et al.
patent: 1 136 079 (2001-09-01), None
patent: 1 258 254 (2002-11-01), None
patent: 2000-159621 (2000-06-01), None
patent: 99/44590 (1999-09-01), None
patent: 00/38676 (2000-07-01), None
Gura et al. Systems for identifying new drugs are often faulty. Science, 1997, 278:1041-1042.
Johnson et al. Relationships between drug activity in NCI preclinical in vitro and in vivo models and early clinical trials. British J. of Cancer, 2001, 84(10):1424-1431.
Chamberlain et al. Innovations and strategies for the development of anticancer vaccines. Expert Opinion on Pharmacology, 2000, vol. 1, pp. 603-614.
Kosaka et al. Prostate, 2007, vol. 67, No. 1, pp. 41-49 (Abstract attached).
Pollard, M. Cancer Letters, 1997, vol. 111, pp. 221-224.
Newling, D.W. Prostate Cancer and Prostatic Diseases, 2000, vol. 3, pp. 290-295.
Y. Fujimoto et al., “Angiotension II type 1 receptor expression in human pancreatic cancer and growth inhibition by angiotension II type 1 receptor antagonist”, FEBS Letters, vol. 495, No. 3, pp. 197-200, 2001.
E. R. Inwang et al., “Antiotension II type 1 receptor expression in human breast tissues”, British Journal of Cancer, vol. 75, No. 9, pp. 1279-1283, 1997.
D. A. Goldfarb et al., “Antiotension II receptor subtypes in the human renal cortex and renal cell carcinoma”, The Journal of Urology, vol. 151, pp. 208-213, Jan. 1994.
S. Marsigliante et al., “AT1 angiotension II receptor subtype in the human larynx and squamous laryngeal carcinoma”, Cancer Letters, vol. 110, pp. 19-27, 1996.
Kubota Yoshinobu
Naito Ken-ichiro
Nakaigawa Noboru
Uemura Hiroji
Anderson James D
Takeda Pharmaceutical Company Limited
Wenderoth , Lind & Ponack, L.L.P.
LandOfFree
Anticancer agents does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Anticancer agents, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Anticancer agents will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4210335